With the advent of high-potency antiretroviral treatment introduced in 1996, HIV infection ceased to be an acute and deadly disease to become chronic and controllable. However, the early aging of this population, which according to some authors and cohorts, is 10 years less than in the "normal" population, has been studied. Although the realities of these patients comorbidities are well known, the definition of time, when and how or with what to treat still seems to be a matter of debate. The aim of this study is to evaluate the incidence and prevalence according to the state of the art for the non-HIV population of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus) and apply the adjusted Framingham Risk Score by recording analytical and clinical factors in an HIV-1 population with more than 50 years of age, followed in the Infectious Diseases Service for more than 6 months.
Characterization of adiposity and inflammation genetic pleiotropy underlying cardiovascular risk factors in Hispanics.
